N@N

Keay Nakae Maintained (ALNY) at Strong Buy with Increased Target to $190 on, Dec 19th, 2019

Keay Nakae of Chardan Capital, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Strong Buy with Increased Target from $150 to $190 on, Dec 19th, 2019.

Keay has made no other calls on ALNY in the last 4 months.

There are 6 other peers that have a rating on ALNY. Out of the 6 peers that are also analyzing ALNY, 1 agrees with Keay's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Esther Rajavelu of "UBS" Maintained at Hold with Increased Target to $96 on, Wednesday, September 4th, 2019

These are the ratings of the 5 analyists that currently disagree with Keay

---

• Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy with Increased Target to $176 on, Wednesday, December 18th, 2019
• David Lebovitz of "Morgan Stanley" Maintained at Buy with Increased Target to $150 on, Tuesday, December 17th, 2019
• Do Kim of "BMO Capital" Maintained at Buy with Increased Target to $143 on, Monday, November 25th, 2019
• Leland Gershell of "Oppenheimer" Initiated at Buy and Held Target at $128 on, Wednesday, November 20th, 2019
• Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $145 on, Tuesday, September 3rd, 2019

Contributing Sources

---